Identification of new inhibitors of dopamine-glutamate receptor heteromerization to alleviate addictive- and depressive-like symptoms
Adèle Vilette, Nicolas Pietrancosta, Peter Vanhoutte · FENS Forum 2024
The high prevalence of comorbidities between substance use disorder (SUD) and other psychiatric diseases, including depression, suggests that brain dysfunctions underlying these disorders may share partly overlapping pathophysiological mechanisms. Identification of such common dysfunctions is therefore a key asset to design therapeutic strategies to treat both SUD and comorbid psychiatric conditions, rather than treating each disease separately, which holds poor efficacy. From mice to humans, we showed that an increase in dopamine (DAR) and glutamate NMDA (NMDAR) receptor heteromerization (i.e
ePoster · Neuroscience